Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Primary Central Nervous System Lymphoma: early-phase trial registry
2 of 3 indexed Refractory Primary Central Nervous System Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Refractory Primary Central Nervous System Lymphoma: 3 US clinical trials tracked, 2 recruiting.
Refractory Primary Central Nervous System Lymphoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Curis, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-primary-central-nervous-system-lymphoma
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Refractory Primary Central Nervous System Lymphoma lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Primary Central Nervous System Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Primary Central Nervous System Lymphoma is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis
NCT03328078
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07082868
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co.
NCT04947319
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Primary Central Nervous System Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Primary Central Nervous System Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Primary Central Nervous System Lymphoma page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Refractory Primary Central Nervous System Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Curis sponsors the most Refractory Primary Central Nervous System Lymphoma trials on record, review their full trial history before evaluating a specific study. See Curis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Primary Central Nervous System Lymphoma condition card totals 3 registered trials; most-linked intervention ibrutinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.